Frequency of Chromosomally-Integrated Human Herpesvirus 6 in Children with Acute Lymphoblastic Leukemia

Annie Gravel¹, Daniel Sinnett², Louis Flamand¹,³*

¹Division of Infectious Diseases and Immunity, CHU de Quebec Research Center, Quebec, Canada, ²Centre de recherche, Service d'hématologie-oncologie, CHU Sainte-Justine, Département de pédiatrie, Université de Montréal, Montreal, Quebec, Canada, ³Department of Microbiology, Infectious Diseases and Immunology, Laval University, Quebec, Quebec, Canada

Abstract

Introduction: Human herpesvirus 6 (HHV-6) is a ubiquitous pathogen infecting nearly 100% of the human population. Of these individuals, between 0.2% and 1% of them carry chromosomally-integrated HHV-6 (ciHHV-6). The biological consequences of chromosomal integration by HHV-6 remain unknown.

Objective: To determine and compare the frequency of ciHHV-6 in children with acute lymphoblastic leukemia to healthy blood donors.

Methodology: A total of 293 DNA samples from children with pre-B (n = 255), pre-pre-B (n = 4), pre-T (n = 26) and undetermined (n = 8) leukemia were analyzed for ciHHV-6 by quantitative TaqMan PCR (QPCR) using HHV-6 specific primers and probe. As control, DNA samples from 288 healthy individuals were used. Primers and probe specific to the cellular GAPDH gene were used to estimate integrity and DNA content.

Results: Out of 293 DNA samples from the leukemic cohort, 287 contained amplifiable DNA. Of these, only 1 (0.35%) contained ciHHV-6. Variant typing indicates that the ci-HHV-6 corresponds to variant A. None of the 288 DNA samples from healthy individuals contained ciHHV-6.

Conclusion: The frequency of ciHHV-6 in children with acute lymphoblastic leukemia is similar (p = 0.5) to that of healthy individuals. These results suggest that acute lymphoblastic leukemia does not originate as a consequence to integration of HHV-6 within the chromosomes.

Introduction

Human herpesvirus-6A (HHV-6A) and HHV-6B are two closely related but distinct viruses belonging to beta-herpesvirus subfamily [1,2]. HHV-6B is a highly prevalent virus and the etiologic agent of roseola infantum, also known as the sixth rash-causing childhood disease [3]. HHV-6B is also a source of concern in hematopoietic transplant recipients where viral reactivations are linked with a variety of medical conditions ranging from mild to life threatening. While HHV-6B is present in nearly 100% of the world’s population, HHV-6A appears to be less frequent in Japan, North America, and Europe. Interestingly, HHV-6A is the predominant variant associated with viremic infant-infections in sub-Saharan Africa [4].

HHV-6 infection generally follows the classical herpesvirus replicative cycle with the release of infectious virions and destruction of the infected cells. For reasons that are unclear, HHV-6 can also integrate the host DNA leading to an “unclassic” form of latency. Work by Arbuckle et al teaches us that in vitro infection can lead to HHV-6 chromosomal integration (ciHHV-6) with a possibility to reactivate and produce infectious HHV-6 [5]. The first in vivo reports of ciHHV-6 date to the early to mid-1990s, when Luppi et al. detected the presence of a partial and possibly full-length integrated HHV-6 genome in the DNA of freshly isolated peripheral blood mononuclear cells (PBMC) [6–8]. In subjects with ciHHV-6, the integrated virus is present at 1 copy/cell suggesting hereditary transmission [9]. Reports estimate that HHV-6 is integrated in the telomeres of approximately 0.2–1% of individuals from Europe, USA and Japan [6,9–13]. By extrapolation, this means that nearly 70 million individuals carry a 170 kilobase insertion (HHV-6 genome size) within their telomeric region. Data so far indicate that HHV-6 genome integration can occur in different chromosomes but invariably takes place in the sub-telomeric or telomeric regions. It is now well established that the self-renewal potential of cells is directly proportional to telomere lengths and telomerase activity [14,15]. The loss of
telomere function can cause cell cycle arrest and apoptosis. Inversely, the loss of telomere function can also lead to genetic instability and cancer progression. It is also known that loss of telomere functions preferentially occurs on the shortest telomeres [16]. When the number of telomeric repeated sequence (TRS) falls below 13, chromosomal instability is observed [17]. Several diseases are linked with telomere dysfunctions and/or telomerase mutations such as hematopoietic dysfunction, pulmonary fibrosis, liver disease, degenerative diseases and cancer [18–29]. Alterations within telomeric regions are therefore a likely cause for cellular dysfunctions linked to diseases but many of the factors affecting telomeres integrity remain to be identified. The HHV-6 integration mechanisms and the biological/medical consequences resulting from this telomeric alteration remain largely unknown but interestingly, ciHHV-6 is 2.3 x more frequent (p<0.001) in diseased (various diseases) individuals relative to healthy ones [30]. Interestingly, integration of Marek’s disease virus (an alpha-herpesvirus of chicken) into the telomeres is linked with the development of T cell lymphoma [31,32]. In this study, we wanted to determine and compare the frequency of ciHHV-6 in children with acute lymphoblastic leukemias (ALL) to healthy blood donors in order to determine whether ciHHV-6 represents a risk factor for such blood malignancies.

Materials and Methods

DNA Samples

Our cohort consisted of 293 childhood ALL patients and 288 healthy controls. Study subjects were all French-Canadians of European descent from the established Quebec Childhood ALL (QcALL) cohort [33]. Incident cases were diagnosed in the Division of Hematology-Oncology at the Sainte-Justine University Health Center (SJUHC), Montreal, Canada, between October 1985 and November 2006. Healthy controls consisted of a group of French-Canadian newborns and adults recruited at the SJUHC. The CHU Sainte-Justine Institutional Review Board approved the research protocol, and written informed consent was obtained from all participating individuals and/or their parents. Tables 1 and 2 list the characteristics of each group.

Real-Time Quantitative PCR (QPCR)

QPCR analyses were performed on a Rotor-Gene Q (Qiagen) with the Rotor-Gene Multiplex PCR Kit (Qiagen) for GAPDH and U65-U66 detection [34]. The following primer pairs have been used: GAPDH gene forward primer, 5’-CGAGATCCCTC-CAAAATCAA-3’; GAPDH gene reverse primer, 5’-TTCA-CACCCATGACGAACAT-3’; GAPDH gene probe, 5’-hexachloro-6-carboxylfluorescein-TGGGAAAGGGCTGGGCTGAT-black-hole-quencher-1-3’; U65-U66 gene reverse primer specific for HHV-6B, 5’-TGGTAAATGGACTAATTGGTGGTTTATT-3’; U65-U66 gene reverse primer specific for HHV-6B, 5’-TTGTTAATGGACTAATTGGTGGTTTATT-3’; U65-U66 gene probe, 5’-carboxylfluorescein-AACAGCTGGCGGAAAAGTGGCAGG-black-hole-quencher-1-3’.

Table 1. Characteristics of control subjects analyzed for ciHHV-6.

| Healthy subject Characteristics | Number (%) |
|--------------------------------|------------|
| Total number of subjects       | 288        |
| Gender                         |            |
| Male                           | 147 (51.0) |
| Female                         | 141 (49.0) |
| Age (years)                    |            |
| Mean                           | 25.2       |
| Median                         | 28.7       |
| Standard deviation             | 5.8 (0 to 69.75) |

Table 2. Characteristics of leukemic subjects analyzed for ciHHV-6.

| Leukemic Patient Characteristics | Number (%) |
|----------------------------------|------------|
| Total number of subjects         | 293        |
| Gender                           |            |
| Male                             | 166 (56.7) |
| Female                           | 127 (43.3) |
| Age (years)                      |            |
| Mean                             | 6.0        |
| Median                           | 4.5        |
| Standard deviation               | 1.5 (0.4 to 17.9) |
| Immunophenotype                  |            |
| Pre-B                            | 255 (87.0) |
| Pre-pre B                        | 4 (1.4)    |
| Pre-T                            | 26 (8.9)   |
| N/D                              | 8 (2.7)    |
| Age group (years)                |            |
| ≤ 1                              | 5 (1.7)    |
| 1-10                             | 230 (78.5) |
| >10                              | 52 (17.7)  |
| N/D                              | 6 (2.1)    |
| Hyperdiploidy                    |            |
| Positive                         | 98 (33.4)  |
| Negative                         | 173 (59.0) |
| N/D                              | 22 (7.6)   |
| Chromosomal translocations       |            |
| Absence of translocation         | 140 (47.8) |
| t(12;21)                         | 40 (13.7)  |
| Other                            | 27 (9.2)   |
| N/D                              | 86 (29.3)  |
| Normal ploidy and absence of     |            |
| chromosomal translocations       | 79 (27.0)  |

Table 1. Characteristics of control subjects analyzed for ciHHV-6. Table 2. Characteristics of leukemic subjects analyzed for ciHHV-6.
Results and Discussion

Detection and identification of individuals carrying ciHHV-6 is relatively simple. Since these individuals carry at least one copy of HHV-6 genome per cell, there is more than a thousand-fold difference in the number of HHV-6 DNA copies/μg of DNA between ciHHV-6 individuals and those that harbor latent episomal (non-integrated) HHV-6 [35]. In fact, the mean number of HHV-6 copies/μg of cellular DNA in individuals with ciHHV-6 is approximately $10^5$ while those with post-natal HHV-6 acquisition are in the range of $10^3$ copies/μg of cellular DNA [10,35,36]. Using leukocytes or any other source of cellular DNA and quantitative polymerase chain reaction (QPCR) assay, it is therefore very easy to identify and distinguish ciHHV-6 from non-ciHHV-6. We use a published and validated TaqMan-based procedure [37] to detect HHV-6A and HHV-6B. This assay can be easily modified to discriminate HHV-6A from HHV-6B [38]. Lastly, as part of a multicenter study conducted across the world, we have reported that this PCR assay is a sensitive and reliable method to detect and quantify HHV-6 [34].

Using these tools, we have screened 581 DNA samples from children with ALL and healthy donors of French-Canadian origin by QPCR using specific primers for HHV-6 U65-U66 gene and GAPDH, as a housekeeping gene. GAPDH amplification was used to assess the quality of the DNA samples and used for normalization. The demographics and characteristics of the control and leukemic subjects are presented in tables 1 and 2, respectively. The age difference between the leukemic subjects (median 4.5 years) and the control subjects (28.1 years) is not an issue considering that ciHHV-6 is inherited [9]. As presented in table 3, all healthy subjects were negative (<10 copies/50 ng of DNA) for the presence of HHV-6 DNA. In our assay, which has a limit of detection of 10 HHV-6 DNA copies, we used 50 ng of genomic DNA meaning that we could only detect subjects with ≥200 copies of HHV-6/μg of DNA. The fact that all healthy subjects were negative for HHV-6 DNA in therefore not unexpected considering the low incidence (10-15%) and low viral loads (median of 62 HHV-6 copies/μg of genomic DNA) reported [39].

In contrast to healthy individuals, DNA samples taken at time of diagnostic from 11 leukemic patients (10 pre-B and 1 pre-T) were positive for HHV-6 DNA (table 3). We determined the HHV-6 copy number in the leukemic patients using a standard curve generated with a plasmid carrying a portion of the U65-U66 gene [37]. We also analyzed all patients using our standard curve for GAPDH, made with a plasmid carrying GAPDH gene. All the data were normalized using the GAPDH copy number. The HHV-6 copy number/μg in ten of these patients varied between 90 and 2410 copies/μg of DNA (median = 320) (table 4). We analyzed the HHV-6 positive patients with primer pairs that discriminate between HHV-6A and HHV-6B. Eight carried HHV-6B and 1 HHV-6A (one could not be not determined). The detection of low HHV-6 viral loads in a small proportion of HHV-6 genome per cell, there is more than a thousand-fold difference in the number of HHV-6 DNA copies/μg of DNA between ciHHV-6 individuals and those that harbor latent episomal (non-integrated) HHV-6 [35]. In fact, the mean number of HHV-6 copies/μg of cellular DNA in individuals with ciHHV-6 is approximately $10^5$ while those with post-natal HHV-6 acquisition are in the range of $10^3$ copies/μg of cellular DNA [10,35,36]. Using leukocytes or any other source of cellular DNA and quantitative polymerase chain reaction (QPCR) assay, it is therefore very easy to identify and distinguish ciHHV-6 from non-ciHHV-6. We use a published and validated TaqMan-based procedure [37] to detect HHV-6A and HHV-6B. This assay can be easily modified to discriminate HHV-6A from HHV-6B [38]. Lastly, as part of a multicenter study conducted across the world, we have reported that this PCR assay is a sensitive and reliable method to detect and quantify HHV-6 [34].

Using these tools, we have screened 581 DNA samples from children with ALL and healthy donors of French-Canadian origin by QPCR using specific primers for HHV-6 U65-U66 gene and GAPDH, as a housekeeping gene. GAPDH amplification was used to assess the quality of the DNA samples and used for normalization. The demographics and characteristics of the control and leukemic subjects are presented in tables 1 and 2, respectively. The age difference between the leukemic subjects (median 4.5 years) and the control subjects (28.1 years) is not an issue considering that ciHHV-6 is inherited [9]. As presented in table 3, all healthy subjects were negative (<10 copies/50 ng of DNA) for the presence of HHV-6 DNA. In our assay, which has a limit of detection of 10 HHV-6 DNA copies, we used 50 ng of genomic DNA meaning that we could only detect subjects with ≥200 copies of HHV-6/μg of DNA. The fact that all healthy subjects were negative for HHV-6 DNA in therefore not unexpected considering the low incidence (10-15%) and low viral loads (median of 62 HHV-6 copies/μg of genomic DNA) reported [39].

In contrast to healthy individuals, DNA samples taken at time of diagnostic from 11 leukemic patients (10 pre-B and 1 pre-T) were positive for HHV-6 DNA (table 3). We determined the HHV-6 copy number in the leukemic patients using a standard curve generated with a plasmid carrying a portion of the U65-U66 gene [37]. We also analyzed all patients using our standard curve for GAPDH, made with a plasmid carrying GAPDH gene. All the data were normalized using the GAPDH copy number. The HHV-6 copy number/μg in ten of these patients varied between 90 and 2410 copies/μg of DNA (median = 320) (table 4). We analyzed the HHV-6 positive patients with primer pairs that discriminate between HHV-6A and HHV-6B. Eight carried HHV-6B and 1 HHV-6A (one could not be not determined). The detection of low HHV-6 viral loads in a small proportion of ALL patients has been observed previously [40,41]. Of these 11 samples, one (P451) had a HHV-6 copy number consistent with ciHHV-6. Relative to a gene such as GAPDH that is present in two copies in a diploid genome, ciHHV-6 is present at one copy per cell, unless both parents carry ciHHV-6, a rather rare occurrence [9]. As presented under table 4, P451 had 511 650 HHV-6A DNA copies per μg of DNA. As positive control, we used DNA from a subject with confirmed ciHHV-6 [5].

The frequency of ciHHV-6 varies between 0.2-3% depending on the geographic area, the sample sized analyzed and disease conditions [reviewed in [30]]. However, when only considering studies with sampling size above 500 subjects, the incidence of ciHHV-6 in healthy individuals from the US or the UK is approximately 1%. HHV-6B represents the integrated virus in two thirds of ciHHV-6 cases [42]. In our cohort, out of 575 individuals tested, 1 ciHHV-6+ individual (0.17%) was detected. The frequency of ciHHV-6 in the Province of Quebec (Canada) therefore appears lower than that observed in US and UK. Furthermore, the one ciHHV-6+ sample detected corresponds to HHV-6A. How can these differences be explained? Our sampling size is certainly one limiting factor preventing us from ascertain with confidence whether the incidence of ciHHV-6 is truly different for the US of the UK. Statistical analysis indicates that the incidence of ciHHV-6 in Quebec does not differ (p = 0.13) from that reported by Hall et al [43]. By expanding the number of subjects, a more precise estimate on the incidence of ciHHV-6 within the population of Quebec would be obtained.

Of interest, the French-Canadian population is considered genetically more homogeneous than other population of European descent due to a limited number of settlers (e.g. founder effect) combined with a large demographic expansion [44]. At present, the Quebec population comprises 7.8 million residents, of which ~80% are French Canadians. The apparent lower frequency of ciHHV-6+ individuals in the province of Quebec could be consequent to initial lower incidence of ciHHV-6 within the settlers.

### Conclusion

The frequency of ciHHV-6 in children with acute lymphoblastic leukemia is similar (p = 0.5) to that of healthy individuals. Our results are in accordance with those of Huiback et al that reported on the frequency of ciHHV-6 in children with acute lymphoblastic
or myeloid leukemia from the Czech Republic [40]. These results suggest that childhood ALL does not originate as a consequence of integration of HHV-6 within the chromosomes.

Acknowledgments

The authors are indebted to all the patients and their parents who consented to participate in this study. We also acknowledge support from the Quebec ALL (Qc-ALL) biobank and Thomas Sontag for the processing and distribution of leukemia cells.

Author Contributions

Conceived and designed the experiments: AG LF. Performed the experiments: AG LF. Analyzed the data: AG LF DS. Contributed reagents/materials/analysis tools: AG LF DS. Wrote the paper: LF.

References

1. Adams MJ, Carstens EB (2012) Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012). Archives of virology 157: 1411–1422.

2. Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, et al. (2013). Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol. [Epub ahead of print] PMID: 24193951

3. Yamazaki K, Okuno T, Shiraki K, Takahashi M, Kondo T, et al. (1988) Identification of human herpesvirus-6 as a causal agent for exantheme subitum [see comments]. Lancet 1: 1065–1067.

4. Bates M, Monze M, Bima H, Kapambwe M, Clark D, et al. (2009) Predominant ciHHV-6 in Leukemia Patients HHV-6 DNA. J Med Virol 73: 465–473.

5. Arbuckle JH, Medvcky MM, Luka J, Hadley SL, Lugmaier A, et al. (2010) The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci USA 107: 5563–5568.

6. Luppi M, Barozzi P, Morris CM, Merelli E, Torelli G (1998) Integration of human herpesvirus 6 genome in human chromosomes. Lancet 352: 1707–1708.

7. Luppi M, Marasca R, Barozzi P, Ferrari S, Ceccherini-Nelli L, et al. (1993) Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J Med Virol 40: 44–52.

8. Torelli G, Barozzi P, Marasca R, Coconcelli P, Merelli E, et al. (1995) Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. J Med Virol 46: 178–188.

9. Daiha M, Tagger T, Nemer Y, Tagger H, Miesch I (1999) Inheritance of chromosomally integrated human herpesvirus 6 DNA. Blood 94: 1545–1549.

10. Hall CB, Caserta MT, Schnabel K, Shelley LM, Marino AS, et al. (2008) Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics 122: 513–520.

11. Luppi M, Barozzi P, Marasca R, Torelli G (1994) Integration of human herpesvirus-6 (HHV-6) genome in chromosome 17 in two lymphoma patients. Leukemia & Suppl 1: S41–45.

12. Nacheva EP, Ward KN, Brazda D, Virgili A, Howard J, et al. (2008) Human herpesvirus 6 integrates within telomeric regions as evidenced by five different chromosomal sites. J Med Virol 80: 1952–1958.

13. Tanaka-Taya K, Sashihara J, Kurahashi H, Amo K, Miyagawa H, et al. (2004) Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA. J Med Virol 73: 465–473.

14. Bodnar AG, Ouellette M, Freikis M, Holt SE, Chiu CP, et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349–352.

15. Hadley CB, Fucker AB, Greider CW (1996) Telomeres shorten during ageing of human fibroblasts. Nature 345: 458–460.

16. Hemann MT, Strong MA, Hao LY, Greider CW (2001) The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107: 67–77.

17. Capper R, Brit-Compton B, Tankianovav M, Rowson J, Lestlzo B, et al. (2007) The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes & development 21: 2395–2500.

18. Armanios MY, Chen JJ, Cogan JD, Alder JS, Ingessell RG, et al. (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. The New England journal of medicine 356: 1317–1326.

19. Arteuchi SE (2006) Telomeres, telomerase, and human disease. N Engl J Med 355: 1195–1197.

20. Calado RT, Regal JA, Hills M, Yesdell WT, Dalmazzlo LF, et al. (2009) Constitutional hypomorph telomerase mutations in patients with acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 106: 1187–1192.

21. Calado RT, Young NN (2009) Telomere diseases. N Engl J Med 361: 2353–2365.

22. Mitchell JR, Wood E, Collins K (1999) A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402: 551–555.

23. O'Sullivan JN, Dornmann MP, Bremstall TA, Finley JC, Shin WT, et al. (2007) Chromosomal instability in ulcerative colitis is related to telomere shortening. Nature genetics 32: 280–284.

24. Ohayashi KI, Ohhashi K, Fujimura T, Kawakubo K, Shimamoto T, et al. (1994) Telomere shortening associated with disease evolution patterns in myelodyplastic syndromes. Cancer research 54: 3557–3560.

25. Qazilbash MH, Liu JM, Vlachos A, Fruchtman S, Messner H, et al. (1997) A new syndrome of familial aplastic anemia and chronic liver disease. Cancer research 57: 164–167.

26. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, et al. (2011) Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470: 359–365.

27. Ullmann T, Marrone A, Dokal I, Mason P (2002) Association between aplastic anemia and mutations in telomerase RNA. Lancet 359: 2168–2170.

Table 4. Detailed analyses of HHV-6 DNA positive patients.

| Leukemic Patients | HHV-6 copies* | HHV-6 % blasts | Diagnostic | Diagnosis age (yr) |
|-------------------|--------------|----------------|-----------|-------------------|
| P101              | 2000         | B              | ND        | 8,3               |
| P331              | 680          | B              | 97.5      | 4.6               |
| P451              | 511650       | A              | 82.0      | 6.8               |
| P454              | 360          | ND             | 83.5      | 6.2               |
| P458              | 2410         | B              | 99.0      | 3.4               |
| P459              | 770          | A              | 97.5      | 2.5               |
| P462              | 90           | B              | 43.2      | 8.7               |
| P467              | 150          | B              | 96.5      | 2.8               |
| P468              | 280          | B              | 100       | 2.8               |
| P478              | 150          | B              | 90.5      | 16.9              |
| P484              | 150          | B              | 89.0      | 11.0              |
| Positive control  | 656180       | A              | NA        | NA                |

*normalized with GAPDH housekeeping gene (µg of DNA).

ND: Not determined; NA: not applicable.

doi:10.1371/journal.pone.0084322.t004
28. Wilkie AO, Lamb J, Harris PC, Finney RD, Higgs DR (1990) A truncated human chromosome 16 associated with alpha thalassaemia is stabilized by addition of telomeric repeat (TTAGGG)n. Nature 346: 868–871.

29. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Bailerlocher GM, et al. (2005) Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. The New England journal of medicine 352: 1413–1424.

30. Pellett PE, Anthiel D, Ambros PF, Agut H, Caserta MT, et al. (2012) Chromosomally integrated human herpesvirus 6: questions and answers. Reviews in medical virology 22: 144–155.

31. Kaufer BB, Jarosinski KW, Osterrieder N (2011) Herpesvirus telomeric repeats facilitate genomic integration into host telomeres and mobilization of viral DNA during reactivation. The Journal of experimental medicine 208: 605–615.

32. Osterrieder N, Kamil JP, Schumacher D, Tischer BK, Trapp S (2006) Marek’s disease virus: from miasma to model. Nat Rev Microbiol 4: 283–294.

33. Healy J, Belanger H, Beaulieu P, Lariviere M, Labuda D, et al. (2007) Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. Blood 109: 683–692.

34. Flamand L, Gravel A, Boutolleau D, Alvarez-Lafuente R, Jacobson S, et al. (2008) Multicenter comparison of PCR assays for detection of human herpesvirus 6 DNA in serum. J Clin Microbiol 46: 2700–2706.

35. Ward KN, Leong HN, Nacheva EP, Howard J, Atkinson CE, et al. (2006) Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles. J Clin Microbiol 44: 1571–1574.

36. Leong HN, Tuke PW, Tedder RS, Khanom AB, Eglin RP, et al. (2007) The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol 79: 45–51.

37. Gautheret-Dejean A, Manichanh C, Thien-Ah-Koon F, Fillet AM, Mangeney N, et al. (2002) Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients. J Virol Methods 100: 27–35.

38. Boutolleau D, Duros C, Bonnafous P, Caila D, Karras A, et al. (2006) Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol 35: 257–263.

39. Geraudie B, Charrier M, Bonnafous P, Heurte D, Desmonet M, et al. (2012) Quantification of human herpesvirus-6A, -6B and -7 DNAs in whole blood, mononuclear and polymorphonuclear cell fractions from healthy blood donors. Journal of clinical virology ; the official publication of the Pan American Society for Clinical Virology 53: 151–155.

40. Hubacek P, Muzikova K, Hrdlickova A, Cinek O, Hyncicova K, et al. (2009) Prevalence of HHV-6 integrated chromosomally among children treated for acute lymphoblastic or myeloid leukemia in the Czech Republic. Journal of medical virology 81: 259–263.

41. Seror E, Coquerel B, Gautheret-Dejean A, Ballerini P, Landman-Parker J, et al. (2008) Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia. J Med Virol 80: 689–695.

42. Morissette G, Flamand L (2010) Herpesviruses and chromosomal integration. J Virol 84: 12100–12109.

43. Hall CB, Caserta MT, Schnabel KC, Boettich C, McDermott MP, et al. (2004) Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr 145: 472–477.

44. Roy-Gagnon MH, Moreau C, Bherer C, St-Onge P, Sinnett D, et al. (2011) Genomic and genealogical investigation of the French Canadian founder population structure. Hum Genet 129: 521–531.